<DOC>
	<DOCNO>NCT00531076</DOCNO>
	<brief_summary>In spite use radiation combine conventional chemotherapy , long-term survival prognosis patient locally advance non-small cell lung cancer disappoint . Much effort currently focus explore new molecular target agent may improve upon survival . The addition agent target blood vessel formation tumor , bevacizumab Avastin , conventional chemotherapy show improve survival metastatic non-small cell lung cancer . Data animal study show bevacizumab related agent also increase tumor cure rate administer radiotherapy . This suggest combined bevacizumab chemo-radiation may improve survival local-advanced disease well . Before clinical study commence , safety normal tissue toxicity profile bevacizumab thoracic radiotherapy must first establish . In study , escalate dos bevacizumab administer radiotherapy , follow maintenance bevacizumab .</brief_summary>
	<brief_title>Safety Study Bevacizumab ( Avastin ) With Thoracic Radiation Non-small Cell Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Cytologically histologically confirm stage II III nonsquamous NSCLC 2 . No evidence tumour invade major blood vessel active hemoptysis ( bright red blood least ½ teaspoon ) 28 day prior randomization . 3 . No prior systemic therapy NSCLC . Prior surgery and/or extrathoracic irradiation permit . 4 . Presence least one measurable target lesion 5 . Age 18 great . 6. WHO performance status 0 1 . 7 . Acceptable pulmonary function define Fev1 ≥30 % DLCO ≥40 % predict 8 . Life expectancy least 12 week . 9 . Adequate hematological , renal hepatic function Absolute neutrophil count &gt; 2x109/l . Platelet count &gt; 100x109/l . Total bilirubin &lt; 1.5 x UNL ASAT/ALAT &lt; 2 x UNL Alkaline phosphatase &lt; 5 x UNL Creatinine &lt; 130 μmol/L Creatinine clearance &gt; 60 ml/min ; measure calculate 10 . Urine dipstick proteinuria &lt; 1+ . If urine dipstick ≥ 1 , 24 hour urine must demonstrate &lt; 500 mg protein 24 hour . 11 . No preexist sensory neurotoxicity grade 2 ( CTC ) 12 . No active ( uncontrolled ) infection require antibiotic Exclusion criterion : 1 . Mixed tumor type small cell lung cancer squamous cell carcinoma 2 . Other serious disease , heart failure , angina pectoris , myocardial infarction within last 6 month , uncontrolled hypertension 3 . Serious nonhealing wound ulcer . 4 . ASAT ALAT &gt; 1,5 x UNL 5. alkaline phosphatase 5 x UNL 6 . Evidence bleed diathesis coagulopathy . 7 . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition assess patient registration trial . 8 . Participation trial investigational drug treatment modality .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>thoracic radiotherapy</keyword>
	<keyword>locally-advanced non-small cell lung cancer</keyword>
</DOC>